ACT Genomics

What ACT Genomics does

ACT Genomics Co., Ltd. is a Taiwan-headquartered precision medicine company founded in 2014 that provides comprehensive genomic profiling services for cancer care across Asian and select European markets. The company operates a portfolio of Next-Generation Sequencing (NGS) based tests covering solid tumor profiling (ACTOnco IVD, the first FDA 510(k) cleared comprehensive cancer genomic profiling product in Asia), liquid biopsy (ACTLiquid Pro/Lite), cancer monitoring (ACTMonitor), hereditary disease testing via whole genome sequencing (ACTInherit), and disease-specific panels (ACTLung, ACTBRCA, ACTHRD, ACTFusion, ACTCerebra, ACTRisk, ACTEGFR, ACTDrug+). Tests are processed at CAP-accredited laboratories and sold through a business-to-business model in which physicians, hospitals, and biopharma companies order tests directly via the company's portal.

The company serves three primary customer segments: (1) healthcare professionals including oncologists, pathologists, and hospitals (200+ hospital and clinic accounts, 700+ physician customers); (2) cancer patients seeking personalized treatment strategies; and (3) biopharma companies requiring comprehensive genomic profiling for biomarker discovery, clinical trial support, and drug development (20+ collaborations). Revenue is generated on a one-time-per-test basis with follow-up monitoring tests producing repeat revenue. The company maintains direct enterprise field sales and Medical Science Liaison engagement across Taiwan, Hong Kong, Japan, Thailand, Singapore, and the United Kingdom, with localized laboratory operations in Thailand holding ISO 15189 and ISO 15190 certifications. Marketing channels include scientific conferences, continuing medical education programs, multi-language web content, patient story publishing, and social media presence.

ACT Genomics was previously a wholly-owned subsidiary of Prenetics Global Limited (NASDAQ: PRE) and was divested in 2025 for $72 million as part of Prenetics' strategic portfolio restructuring; the company currently identifies as a member of Delta Group, a diversified conglomerate. The company holds CAP laboratory accreditation, ISO/IEC 27001:2022 and ISO/IEC 27701:2019 information security and privacy certifications, and has integrated AI capabilities (NLP, RAG-based generative AI) for clinical workflow support including automated medical information retrieval and patient case summarization. Headcount is reported at 251-500 employees.

Name

ACT Genomics

Legal name

ACT Genomics Co., Ltd.

Website

https://actgenomics.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

101–250 employees

Short description

ACT Genomics is a Taiwan-based precision medicine company founded in 2014 that provides NGS-based comprehensive genomic profiling tests for cancer care to oncologists, hospitals, biopharma partners, and patients across Asia and the UK, anchored by the FDA 510(k) cleared ACTOnco IVD.

Ownership category

akta.pro rank

Product category

Cancer Genomic Diagnostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

akta.pro secondary industries

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Genomic Profiling & Sequencing-Based Precision Medicine (HLAAANAA), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)

Keywords

• Cancer genomic profiling
• Liquid biopsy testing
• Precision oncology diagnostics
• Next-generation sequencing
• Companion diagnostics

Headquarters

HQ city

Taipei

HQ country

Taiwan

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Genomic Testing Services: ACT Genomics generates revenue through providing genomic testing services to healthcare providers, hospitals, clinics, and biopharma companies. Tests are ordered by physicians for cancer patients requiring treatment guidance, recurrence monitoring, or drug selection. Revenue is primarily one-time per test basis with follow-up monitoring tests generating repeat revenue.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels9 records

Core offering

ACT Genomics is a precision oncology company that provides next-generation sequencing (NGS)-based comprehensive genomic profiling, liquid biopsy, hereditary cancer, and recurrence monitoring tests for cancer patients. Its tests are ordered by oncologists and pathologists at hospitals and are also used by biopharma clients for biomarker discovery and companion diagnostic development. The portfolio includes the FDA 510(k)-cleared ACTOnco IVD plus organ-specific and indication-specific assays such as ACTDrug+, ACTLung, ACTBRCA, ACTHRD, ACTFusion, ACTLiquid Pro/Lite, ACTMonitor, and ACTInherit.

Product overview

ACT Genomics is a precision medicine company offering a comprehensive portfolio of genomic testing products and services for cancer care. The portfolio includes FDA 510(k) cleared ACTOnco IVD as the flagship product, complemented by liquid biopsy solutions (ACTLiquid Pro, ACTLiquid Lite), drug response tests (ACTDrug+, ACTDrug), cancer-specific panels (ACTBRCA, ACTHRD, ACTLung, ACTFusion), monitoring solutions (ACTMonitor), risk assessment (ACTRisk), and hereditary disease testing (ACTInherit). Services are organized into three segments: For Professionals (comprehensive and targeted genomic panels), For Patients (personalized treatment planning), and For Biopharma (biomarker discovery and comprehensive genomic profiling for drug development). The company recently integrated AI capabilities for clinical diagnosis workflows including automated medical information retrieval, case summarization, and disease prediction.

Differentiator

Problem solved

Functional benefit

Brands

• ACTOnco: Comprehensive genomic profiling test for solid tumors, including US FDA 510(k) cleared ACTOnco IVD product for Asian patients
• ACTLiquid
• ACTDrug
• ACTMonitor
• ACTBRCA
• ACTHRD
• ACTLung
• ACTFusion
• ACTRisk
• ACTCerebra
• ACTEGFR
• ACTNonet
• ACTInherit

Products and services

• ACTOnco IVD

Quantifiable outcome

• First Asian company to achieve US FDA 510(k) clearance for comprehensive cancer genomic testing
• +3 more outcomes

Named customers7 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature11 records

Partnerships

Five partnerships are on record, tiered core and supporting.

• Delta Group (Member)coreStrategic or Co-development Partner · 1 January 2024ACT Genomics is a member of Delta Group, a major technology conglomerate. The parent company relationship provides strategic alignment and potential synergies in precision medicine and healthcare technology development. The Terms of Use and Privacy Policy reference Delta Group affiliation.
• Hospital and Clinic NetworkscoreStrategic or Co-development Partner200+ hospital and clinic accounts across Asia-Pacific region using ACT Genomics testing services for cancer patient care. These healthcare institutions rely on ACT Genomics' comprehensive genomic profiling to guide treatment decisions for solid tumor cancers.
• Biopharma and Research InstitutionscoreStrategic or Co-development Partner20+ biopharma and research institute collaborations for clinical diagnostics and research. ACT Genomics supports pharmaceutical companies in biomarker discovery, clinical trial support, and comprehensive genomic profiling services for drug development.
• SGS (Certification Body)supportingImplementation/ SI/ Consulting PartnerSGS provides ISO 27001 and ISO 27701 certification services for ACT Genomics' information security and privacy management systems, validating compliance with international standards.
• College of American Pathologists (CAP)supportingImplementation/ SI/ Consulting PartnerCAP provides laboratory accreditation services ensuring ACT Genomics laboratories meet the most stringent international laboratory standards for quality and competence.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Personalis: Personalis offers NGS-based CGP including NeXT Personal for tumor profiling and minimal residual disease — overlapping with ACT's oncology NGS franchise.
• Burning Rock Biotech: China-based oncology NGS company focused on cancer therapy selection and monitoring — comparable CGP/liquid biopsy positioning in the broader Asia oncology market.
• Caris Life Sciences: Caris provides comprehensive molecular profiling (tissue + liquid) with MI Profile and Caris Assure — comparable to ACT's tissue CGP and liquid biopsy menu.
• Guardant Health: Guardant360 is a leading liquid biopsy CGP test in oncology — directly overlapping with ACT's ACTLiquid and ACTOnco comprehensive genomic profiling offerings for solid tumors.
• Genecast Biotechnology: Asia-focused oncology genomic profiling services for solid tumors — directly comparable to ACTOnco and ACTLiquid in patient population and regional footprint.
• Tempus AI: Tempus offers comprehensive genomic profiling plus AI-enabled clinical decision support for oncology — directly analogous to ACT's combined NGS + AI clinical workflow offering.

Broad incumbents

• NeoGenomics: Provides a broad oncology-focused laboratory services menu including NGS CGP — broader incumbent that competes with ACT for hospital oncology testing volume.
• Foundation Medicine: Roche-owned leader in tissue-based CGP with FoundationOne CDx — broad incumbent whose FDA-cleared CGP product competes directly with ACTOnco IVD globally.

Regional players

• MedGenome: India-headquartered genomics services provider with oncology and hereditary NGS panels — analogous offering but different geography from ACT's Asia focus.
• Novogene: Major Asia-based NGS sequencing services provider, including clinical and oncology applications — comparable NGS capability in adjacent Asian markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCzNdxh7lK1SrEUrv59g_3IA
• Facebookfacebook.com/ACTGenomicsSG
• LinkedInlinkedin.com/company/act-genomics
• Instagraminstagram.com/actgenomicssg

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds4 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ACT Genomics